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SUMMARY
Dystroglycan, which serves as a major extracellular matrix receptor in muscle and the central
nervous system, requires extensive O-glycosylation to function. We identified a dystroglycan
missense mutation (Thr192→Met) in a woman with limb-girdle muscular dystrophy and cognitive
impairment. A mouse model harboring this mutation recapitulates the immunohistochemical and
neuromuscular abnormalities observed in the patient. In vitro and in vivo studies showed that the
mutation impairs the receptor function of dystroglycan in skeletal muscle and brain by inhibiting
the post-translational modification, mediated by the glycosyltransferase LARGE, of the
phosphorylated O-mannosyl glycans on α-dystroglycan that is required for high-affinity binding to
laminin.
MUSCULAR DYSTROPHIES ARE GENETIC DISEASES CHARACTERIZED BY
weakness and progressive degeneration of skeletal muscle. The transmembrane protein
dystroglycan, which is ultimately cleaved into an α and a β component, is a key link between
the cytoskeleton and extracellular-matrix proteins that bear laminin globular domains (e.g.,
laminin, agrin, and neurexin).1,2 The mucin domain of α-dystroglycan is modified with
numerous O-linked oligosaccharides that are essential for its normal function as an
extracellular-matrix receptor in various tissues, including skeletal muscle and brain.2,3
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Hypoglycosylation of α-dystroglycan and a consequent reduction of α-dystroglycan binding
to extracellular-matrix proteins are observed in patients with the Walker–Warburg
syndrome, muscle–eye–brain disease, Fukuyama-type congenital muscular dystrophy,
congenital muscular dystrophy types 1C and 1D, and limb-girdle muscular dystrophy 2I.2
To date, genes encoding six putative and known glycosyltransferases (POMT1, POMT2,
POMGnT1, LARGE, FKTN, and FKRP) have been shown to be responsible for
approximately 50% of cases of these diseases, which are collectively referred to as
secondary dystroglycanopathies4–11 and which often feature brain abnormalities as well as
muscular dystrophy. Despite recent advances in our understanding of the molecular
mechanisms underlying secondary dystroglycanopathies, it remains unclear whether
dystroglycan is the only target of these enzymes or whether other substrates contribute to the
pathogenesis of these diseases.
Dystroglycan is known to be modified with several classes of oligosaccharides: N-glycans,
mucin-type O-glycans, and O-mannosyl glycans.2 The O-mannosyl glycans are thought to
be responsible for dystrogly-can’s ligand-binding activity because the POMT1–POMT2
protein complex catalyzes the transfer of mannose to serine or threonine residues by means
of an O-linkage.2 We recently reported that maturation of α-dystroglycan to its laminin-
binding form requires a novel biosynthetic pathway involving phosphorylation on O-
mannosyl glycans and that LARGE is crucial for further modification of phosphorylated O-
mannosyl glycans on α-dystroglycan.12
Here we report a missense mutation in the dystroglycan-encoding gene, DAG1, in a patient
with limb-girdle muscular dystrophy and cognitive impairment. Our studies revealed that
this substitution interferes with LARGE-dependent maturation of phosphorylated O-
mannosyl glycans on α-dystroglycan and leads to the disease-causing defect of α-
dystroglycan binding to laminin.
METHODS
CLINICAL INFORMATION
The patient initially received a diagnosis of limb-girdle muscular dystrophy with mental
retardation.13 Clinical data regarding this patient have been reported elsewhere.14 (See also
the Supplementary Appendix, available with the full text of this article at NEJM.org.) This
study was approved by the institutional review board at Hacettepe University, and written
informed consent was obtained from the patient’s guardians.
BIOCHEMICAL ANALYSIS
Biochemical analyses, including Western blotting, laminin-binding assays, and protein pull-
down assays, were carried out as previously described.3,15 (For details about the cell-culture
and biochemical methods used, see the Supplementary Appendix.)
MOUSE MODEL
Protocols for generating a knock-in mouse model harboring a mutation equivalent to that in
our patient, as well as animal care and animal procedures, were approved by the University
of Iowa Animal Care and Use Committee (see the Supplementary Appendix).
RESULTS
We studied a Turkish patient with a relatively mild form of muscular dystrophy
accompanied by cognitive impairment (see Case 2 in Dinçer et al.14). Although
immunofluorescence analysis showed that α-dystroglycan was hypoglycosylated in this
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patient, no mutation was found in genes previously implicated in the pathogenesis of
secondary dystroglycanopathies.14 Since the dystroglycan-encoding gene, DAG1, is a
plausible candidate gene, we investigated whether our patient harbored a causative mutation
therein. Sequencing of the coding and noncoding regions of DAG1 revealed a homozygous
C-to-T missense mutation at position c.575, causing substitution of a methionine for a
threonine at amino acid residue 192 (T192→M) of the protein (Fig. 1A). Both parents were
heterozygous carriers of this mutated allele, and allele segregation in the family was
consistent with recessive disease inheritance (Fig. 1B). The mutated threonine residue is
located in the α-dystroglycan N-terminal and is highly conserved across species (Fig. 1C).
We first assessed the effect of the newly identified α-dystroglycan mutation in vitro, with
respect to expression, post-translational processing, or both. To this end, we transiently
expressed the full-length wild-type and T192→M dystroglycan proteins in dystroglycan-null
myoblasts. Western blotting with an antibody that recognizes functionally glycosylated α-
dystroglycan (IIH6)3,15 revealed considerably lower immunoreactivity for T192→M than
for wild-type dystroglycan when similar amounts of protein were expressed (Fig. 1D).
Biotinylation analysis revealed that the cell-surface expression of T192→M and wild-type
dystroglycan was similar (Fig. 1A in the Supplementary Appendix). Thus, in myoblasts, the
T192→M substitution affects neither protein localization nor protein stability, but it does
impair post-translational modification. A laminin-binding assay confirmed that the
T192→M mutation considerably reduces the effectiveness of dystroglycan as a laminin
receptor (Fig. 1D, and Fig. 1B and 1C in the Supplementary Appendix).
We next assessed the effect of the T192→M mutation on functional modification of α-
dystroglycan in vivo by introducing a T190→M mutation (which corresponds to the human
T192→M mutation) into the mouse Dag1 gene (Fig. 2 in the Supplementary Appendix).
Histologic analysis revealed hallmarks of muscular dystrophy, such as centrally nucleated
fibers, in the mutant mice (Fig. 2A, and Fig. 3A and 4 in the Supplementary Appendix).
Immunofluorescence and biochemical analyses showed that the mutated α-dystroglycan was
expressed at the skeletal-muscle sarcolemma but that both ligand-binding activity and IIH6
reactivity at this location were considerably decreased (Fig. 2B, and Fig. 3B and 5 in the
Supplementary Appendix). Analysis of the uptake in the diaphragm of the membrane-
impermeable Evans blue dye revealed disruption of the skeletal-muscle sarcolemma in the
T190→M mice after exercise (Fig. 2C). The mutant mice also had marked impairment of
exercise performance (e.g., reduced forelimb grip strength) (Fig. 2D). Mice heterozygous for
the T190→M mutation did not have obvious muscle defects at the histologic level, despite a
slight reduction in functional glycosylation of α-dystroglycan (Fig. 4 and 6 in the
Supplementary Appendix). Thus, the T190→M mutation caused skeletal-muscle
abnormalities in mice that were consistent with those observed in our patient.
In addition to its role in skeletal muscle, dystroglycan is crucial for maintaining the structure
and function of the brain and neuromuscular junctions.3,16–18 Western blot and laminin-
overlay analyses revealed that laminin-binding activity was significantly diminished in the
brains of mice with the T190→M mutation (Fig. 3A). Morphologic analysis of the
neuromuscular junctions revealed that the T190→M mutation interfered with their
maturation; on staining of diaphragm samples with a-Bungarotoxin conjugated with Alexa
Fluor 488 (Invitrogen), which tightly binds acetylcholine receptors, the neuromuscular
junctions in wild-type animals formed the expected pretzel-like structure, whereas those in
the T190→M mice were round and immature (Fig. 3B and 3C, and Fig. 7 in the
Supplementary Appendix). Consistent with impaired neuromuscular-junction maturation
was the observation that the mutant mice had marked deficiencies in assays of
neuromuscular function — for example, a reduction in retention time on a rotating-rod
device (Fig. 3D). Furthermore, although no structural abnormality was evident in the brains
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of the T190→M mice (an observation that was consistent with the results on magnetic
resonance imaging [MRI] of the patient’s brain), these mice had abnormal hind-limb
clasping, a phenotype common to mouse models featuring neurologic impairment (Fig. 8 in
the Supplementary Appendix). Collectively, these results provide strong evidence that the
mutation in the patient caused neurologic impairment as well as muscular dystrophy as a
consequence of impaired α-dystroglycan post-translational modification.
Dystroglycan is also expressed in cardiac muscle, where its function as an extracellular-
matrix receptor is important for limiting activity-induced myocardial damage.19 Given that
some patients with mutations in FKTN and FKRP have dilated cardiomyopathy,20,21 we
analyzed cardiac tissue from T190→M mice. We observed no obvious signs of any
pathological abnormality, such as fibrosis or uptake of Evans blue dye after exercise (Fig. 9
in the Supplementary Appendix). Moreover, in contrast to the observed effects in brain and
skeletal muscle, laminin-binding activity was affected only minimally in the hearts of
T190→M mice (Fig. 3A). Thus, it appears that normal cardiac function is maintained in
T190→M knock-in mice and that the effects of the mutation on functional modification of
α-dystroglycan are tissue-dependent.
Mutations in LARGE have been identified in patients with the Walker–Warburg syndrome
or congenital muscular dystrophy type 1C, as well as in mice with myodystrophy
(Largemyd).9,10,22 We recently found that LARGE is essential for phosphorylated O-
mannosyl glycans to mature into a form capable of binding laminin.12 We investigated the
glycosylation status of T190→M α-dystroglycan by subjecting the protein to treatment with
cold aqueous hydrofluoric acid, which cleaves phosphoester linkages, and to inorganic
metal–affinity chromatography, which captures monoester-linked phosphorylated
compounds. Hydrofluoric acid treatment clearly reduced the molecular weight of T190→M
α-dystroglycan, and the beads on chromatography failed to capture T190→M α-
dystroglycan, although they readily bound α-dystroglycan in samples from Largemyd
animals (Fig. 10 in the Supplementary Appendix). These results suggest that T190→M α-
dystroglycan bears phosphorylated O-mannosyl glycans but that these moieties are not
sufficiently mature to confer laminin-receptor function on α-dystroglycan.
Our findings suggest that the T192→M mutation affects LARGE-dependent modification of
α-dystroglycan. A previous study showed that the dystroglycan N-terminal serves as a
binding site for LARGE, an interaction that is essential for α-dystroglycan’s laminin-binding
activity.15 An in silico model suggested that the side chain of the methionine residue could
affect the protein surface structure23 (Fig. 11A in the Supplementary Appendix);
accordingly, we hypothesized that the T192→M mutation abrogates the dystroglycan–
LARGE interaction owing to a conformational change in the dystroglycan N-terminal. A
pull-down assay with Fc-tagged α-dystroglycan mutants showed that although the wild-type
protein bound to LARGE, variants harboring the T192→M mutation did not (Fig. 11B and
11C in the Supplementary Appendix). These findings support the notion that the T192→M
mutation in dystroglycan dramatically impairs the interaction between α-dystroglycan and
LARGE, leading to incomplete post-translational modification of α-dystroglycan.
DISCUSSION
Although genes responsible for O-glycosylation–dependent muscular dystrophy (i.e.,
dystrogly-canopathy) have been identified, the molecular mechanisms whereby mutations
therein lead to impaired skeletal-muscle and brain function remain elusive — in part because
defects in dystroglycan itself have not been reported. Here we describe such a case, which
represents a new disease class (i.e., primary dystroglycanopathy). The T192→M mutation in
this case caused deficiencies in α-dystroglycan glycosylation and a marked reduction in α-
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dystroglycan’s ability to bind extracellular-matrix components. Furthermore, our knock-in
mouse model harboring the patient’s mutation recapitulates the phenotype of secondary
dystroglycanopathies in humans, supporting the view that dystroglycan is the main — and
probably only — protein that is subject to the glycosylation abnormalities that cause
muscular dystrophy.
Patients with dystroglycanopathy have a broad spectrum of disease phenotypes, with or
without brain involvement. Limb-girdle muscular dystrophy with mental retardation was
diagnosed in our patient according to the classification system established by Godfrey et
al.13 Biochemical findings from analyses of mouse T190→M show that laminin-binding
activity is considerably reduced (Fig. 1 and 2), suggesting that residual glycosylation may
account for the relatively mild muscle phenotype, as compared with the findings in patients
with other congenital muscular dystrophies.
Our patient had severe cognitive impairment, yet MRI revealed no gross structural
abnormality in the brain.14 In more severe cases of human dystroglycanopathy, as well as in
mice with a brain-specific Dag1 knock-out, structural as well as functional brain
abnormalities have been documented.3–6,9,10,16 Thus, it may be that residual laminin binding
by human T192→M dystroglycan is sufficient for the development of the cerebral layer but
not for the establishment of normal synaptic physiology. It remains unclear how
dystroglycan contributes to synaptic physiology; however, reports that synaptic components
possessing laminin globular domains play a fundamental role in establishing and
maintaining synaptic function24,25 suggest that a reduction in the affinity of dystroglycan for
synaptic proteins could be responsible for the neurologic phenotypes observed in the patient
described here.
Our biochemical analyses show that the T192→M mutation impairs maturation of a specific
modification of phosphorylated O-mannosyl glycans on α-dystroglycan (Fig. 10 in the
Supplementary Appendix). In the heart, T190→M α-dystroglycan maintains substantial
laminin-binding activity despite a reduction in molecular weight consistent with that in
skeletal muscle and brain (Fig. 2 and 3A), and this remaining activity may contribute to
preserved cardiac function (Fig. 8 in the Supplementary Appendix). The tissue variability in
levels of α-dystroglycan’s functional glycosylation remains unexplained, but there are
several possible explanations (e.g., tissue-specific protein complexes might increase the
affinity between dystroglycan and LARGE, or the enzymatic activity of LARGE might be
enhanced in heart tissue). Further investigation will be required to delineate the tissue-
specific mechanisms ensuring that phosphorylated O-mannosyl residues of α-dystroglycan
mature into laminin-binding glycans.
In conclusion, we found a pathogenic missense mutation in DAG1 that selectively impairs
further modification of phosphorylated O-mannosyl glycans on α-dystroglycan, leading to
neuromuscular abnormalities. Our findings constitute evidence for the inclusion of DAG1 in
the list of genes whose mutations cause muscular dystrophy and cognitive impairment in
humans.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Identification of a DAG1 Missense Mutation in a Woman with Limb-Girdle Muscular
Dystrophy, and In Vitro Biochemical Characterization of the Encoded Protein
In Panel A, electrochromatograms reveal sequence variation in DAG1. A homozygous
mutation, c.575C→T (arrow), leads to an amino acid change, T192→M. The T192→M
variant was not detected in any of the 100 Turkish control subjects tested (200
chromosomes). Panel B shows the family pedigree. Squares denote male family members,
and circles female family members; the double line indicates a consanguineous marriage;
the black circle denotes the affected woman, and dots indicate heterozygous carriers. Panel
C shows a schematic representation of a dystroglycan mutant protein (top). Human α-
dystroglycan is composed of a signal peptide (SP) (amino acids 1 through 29), an N-terminal
domain (amino acids 30 through 316), a mucinlike domain (amino acids 317 through 485),
and a C-terminal domain (amino acids 486 through 653). The position of the patient’s
mutation (T192→M) is indicated by an asterisk. Amino acid residues are aligned flanking
the codon affected by the T192→M missense mutation (bottom). Among these residues,
black boxes denote identity and gray boxes similarity. Panel D shows a biochemical analysis
of wild-type (WT-DG) and T192→M dystroglycan in dystroglycan-null myoblast cells.
Functional modification of α-dystroglycan was evaluated by Western blotting with an
antibody (IIH6) that recognizes only the glycosylated form of α-dystroglycan and by
laminin-overlay assay. Overall expression of wild-type dystroglycan and T192→M
dystroglycan was detected with the use of antibodies against the α-dystroglycan protein core
(CORE) and antibodies against β-dystroglycan (β-DG).
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Figure 2. Biochemical and Physiological Skeletal-Muscle Phenotypes of Disease in Gene-
Targeted Mice with the Same Dystroglycan Mutation as the Patient
Panel A shows immunofluorescence and histologic analyses of T190→M skeletal-muscle
(iliopsoas) sections prepared when the animals were 21 weeks of age. Serial sections were
stained with antibodies against glycosylated α-dystroglycan (IIH6), the α-dystroglycan core
(CORE), and β-dystroglycan (β-DG). Histologic abnormalities in the sections were
evaluated by means of hematoxylin and eosin (H and E) staining. White arrowheads indicate
centrally nucleated fibers (scale bar, 50 μm). Panel B shows a representative biochemical
analysis of wild-type (WT) and T190→M α-dystroglycan isolated from wheat-germ
agglutinin–enriched homogenates of skeletal muscle. Both Western blotting and laminin-
overlay assays were carried out. Functional modification of α-dystroglycan was impaired by
the T190→M mutation in vivo, as shown by the dramatic reduction in IIH6
immunoreactivity and laminin binding in the absence of major differences in CORE and β-
DG immunoreactivity. Panel C shows the uptake of Evans blue dye in the diaphragm after
exercise in wild-type and T190→M mice at 8 weeks of age. Panel D shows the whole-
mouse grip-strength measurements, in gram-force (g–F), for the T190→M mice and their
wild-type littermates. The P value was obtained with the use of Student’s t-test.
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Figure 3. Neuromuscular Phenotypes in Mice with the Dystroglycan Mutation
Panel A shows functional modification of α-dystroglycan in the brain and heart of mice with
the T190→M mutation. Antibody staining and laminin-overlay assays were performed on
blots of wheat-germ agglutinin–enriched homogenates from the brain and heart of T190→M
mice and their wild-type (WT) littermates. Panels B and C show defects in maturation of the
neuromuscular junction (NMJ) in the T190→M mice. Panel B shows representative images
of the NMJ in the diaphragm; specimens were stained, with α-Bungarotoxin labeled with
Alexa Fluor 488 (scale bar, 10 μm). Panel C shows individual data (circles) and mean (±SE)
values for the NMJ area in wild-type and T190→M mice. Panel D shows the mean (±SE)
values of five rotating-rod trials performed to assess neurologic defects in the T190→M
mice. The time that the mice remained on the rotating rod was significantly longer for the
wild-type mice than for the T190→M mice (P<0.001 by one-way analysis of variance).
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